This report will provide valuable strategic insight to CTM manufacturers and contract service providers alike
Fairfax, VA (PRWEB) September 11, 2008
Five years ago only a handful of CROs and CMOs were manufacturing clinical batches of injectables, leaving bio/pharmaceutical companies to scramble for fill/finish capacity. This PharmSource report analyzes the prospect of whether clinical trial materials (CTM) injectable manufacturing capacity may be headed to overcapacity today.
The Injectable CTM Manufacturing Market compares manufacture of drug candidate, development and placebo batch manufacturing needs with projections and manufacturing capacity to illustrate the current supply/demand balance. "This report will provide valuable strategic insight to CTM manufacturers and contract service providers alike," comments PharmSource founder and president, Jim Miller. The $495 report will be offered as a free download to interested parties from September 10th through September 15, 2008 at the PharmSource website : http://www.pharmsource.com/forms.cfm?id=30
PharmSource Information Services, Inc. is a respected provider of contract drug development and manufacturing intelligence. Since 1996 PharmSource has assisted Biotechnology and Pharmaceutical companies with the implementation and management of sourcing strategies and tactics through insightful publications, analyses and intelligence services. Visit PharmSource on the web at http://www.pharmsource.com or contact them at 703-383-4903.